menu search

TCRR / TCR² Therapeutics: Refocused Pipeline Puts It On A Solid Path

TCR² Therapeutics: Refocused Pipeline Puts It On A Solid Path
Reprioritization of pipeline sees 40% reduction of workforce with enough cash to fund pipeline into early 2025. Proof of concept established using gavo-cel for the treatment of patients with mesothelin tumors; Focus shift more towards targeting ovarian cancer patients with expected data 2nd half of 2023. Read More
Posted: Feb 15 2023, 06:00
Author Name: Seeking Alpha
Views: 090584

TCRR News  

Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?

By InvestorPlace
March 6, 2023

Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?

TCR2 Therapeutics (NASDAQ: TCRR ) stock is jumping more than 30% in early trading on March 6 after the company agreed to merge with Adaptimmune (NASDA more_horizontal

TCR² Therapeutics: Refocused Pipeline Puts It On A Solid Path

By Seeking Alpha
February 15, 2023

TCR² Therapeutics: Refocused Pipeline Puts It On A Solid Path

Reprioritization of pipeline sees 40% reduction of workforce with enough cash to fund pipeline into early 2025. Proof of concept established using gav more_horizontal

TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference

By GlobeNewsWire
November 23, 2022

TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference

CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of no more_horizontal


Search within

Pages Search Results: